August 2, 2024

INNOVITA (Tangshan) Biological Technology Co., Ltd. $\%$ Jenny Xia   
Director   
LSI International Inc   
504 East Diamond Ave., Suite I   
Gaithersburg, Maryland 20877

Re: K241919 Trade/Device Name: Innovita HCG Pregnancy Rapid Combo Test Regulation Number: 21 CFR 862.1155 Regulation Name: Human chorionic gonadotropin (HCG) test system Regulatory Class: Class II Product Code: JHI Dated: June 28, 2024 Received: July 1, 2024

Dear Jenny Xia:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safetyreporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical  
devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn   
(https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Paula V. Caposino -S

Paula Caposino, Ph.D.   
Deputy Division Director   
Division of Chemistry and   
Toxicology Devices   
OHT7: Office of In Vitro Diagnostics   
Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

# Indications for Use

<table><tr><td rowspan=1 colspan=1>Submission Number (if known)</td></tr><tr><td rowspan=1 colspan=1>k241919</td></tr><tr><td rowspan=1 colspan=1>Device Name</td></tr><tr><td rowspan=1 colspan=1>Innovita HCG Pregnancy Rapid Combo Test</td></tr><tr><td rowspan=1 colspan=1>Indications for Use (Describe)</td></tr></table>

lnnovita HCG Pregnancy Rapid Combo Test is a rapid chromatographic immunoassay for the qualitative detection of human chorionic gonadotropin in urine or serum to aid in the early detection of pregnancy. The test is for health care professionals use including professionals at point of care (POC).

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid 0MB number."

# 510(k) SUMMARY K241919

1. Date:   
2. Submitter:

July 30, 2024   
INNOVITA (Tangshan) Biological Technology Co., Ltd. No. 699 Juxin Street, High-tech Industrial Development Zone,   
Qian'an, Hebei, 064400, China.

3. Contact person:

Jenny Xia   
LSI International Inc.   
504 East Diamond Ave., Suite I Gaithersburg, MD 20877   
Telephone: 301-525-6856   
Fax: 301-916-6213   
Email: jxia@lsi-consulting.org

4. Device Name:

Innovita HCG Pregnancy Rapid Combo Test

Classification: ClassII   

<table><tr><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>CFR #</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>JHI</td><td rowspan=1 colspan=1>862.1155, Human chorionicgonadotropin (HCG) test system</td><td rowspan=1 colspan=1>Clinical Chemistry</td></tr></table>

5. Predicate Devices:

K203272, Alltest Pregnancy Rapid Combo Test Cassette

6. Intended Use

The Innovita HCG Pregnancy Rapid Combo Test is a rapid chromatographic immunoassay for the qualitative detection of human chorionic gonadotropin in urine or serum to aid in the early detection of pregnancy.

The test is for health care professionals use including professionals at point of care (POC).

7. Device Description

The Innovita HCG Pregnancy Rapid Combo Test measures the presence of the hormone Human Chorionic Gonadotrophin (HCG) in human urine or serum for the early detection of pregnancy. During pregnancy, HCG is produced by the placenta shortly after the embryo attaches to the uterine lining. The test device is used as a single cassette device.

8. Substantial Equivalence Information

A summary comparison of features of the Innovita HCG Pregnancy Rapid Combo Test and the predicate device is provided in the following table.

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Rapid qualitative detection ofHG to aid in the early detectionof pregnancy.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Urine or serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Principle</td><td rowspan=1 colspan=1>Lateral flow SandwichImmunochromatographic Assay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Detection reagent</td><td rowspan=1 colspan=1>Colloidal gold</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Read time</td><td rowspan=1 colspan=1>5 minutes for both serum and urine</td><td rowspan=1 colspan=1>Serum: 5 minutesUrine: 3 minutes</td></tr><tr><td rowspan=1 colspan=1>Usage</td><td rowspan=1 colspan=1>For prescription use</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Cut-Off Values</td><td rowspan=1 colspan=1>10 mIU/mL for serum and 20mIU/mL for urine</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Configurations</td><td rowspan=1 colspan=1>Cassette</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>4- 30</td><td rowspan=1 colspan=1>2 -30°C</td></tr></table>

9. Test Principle

The kit is a double antibody sandwich immunochromatographic assay that detects the presence of HCG in human serum or urine specimens. Anti $\beta$ -HCG antibodies conjugated with colloidal gold is deposited on the conjugate pad, and Anti ${ \bf { d } }$ -HCG antibodies are immobilized on the test line of the nitrocellulose membrane. When the specimen is applied, the gold-antibody conjugate is rehydrated and the HCG, if there is sufficient HCG in the specimen, interacts with the gold-conjugated antibodies. The antigen-antibody-gold complex then migrates towards the test window until the Test Zone (T) where it gets captured by immobilized antibodies, forming a visible redpurple line (Test line), indicating a positive result. If HCG is absent from the specimen, no red-purple line will be visible in the Test Zone (T), indicating a negative result.

To serve as an internal process control, a control line should always appear at Control Zone (C) after the test is completed. Absence of a red-purple control line in the Control Zone(C) indicates an invalid result.

10. Performance Characteristics Analytical Performance a. Precision/Reproducibility/Cut-Off Value Negative serum or urine specimens from females were spiked with varying HCG (commercially available and traceable to the 5th WHO international Standard)

concentrations. The spiked samples were measured in 6 replicates each day for 5 days using 3 different lots at three testing sites. Tests were performed by six different operators for each sample concentration. Results are shown in the following tables.

Serum   

<table><tr><td rowspan=2 colspan=1>HCGConcentration(mIU/mL)</td><td rowspan=1 colspan=2>Site 1Lot 1</td><td rowspan=1 colspan=2>Site 2Lot 2</td><td rowspan=1 colspan=2>Site 3Lot 3</td><td rowspan=1 colspan=2>Totalresult</td><td rowspan=2 colspan=1>%Negative</td><td rowspan=2 colspan=1>%Positive</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>46.7</td><td rowspan=1 colspan=1>53.3</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr></table>

Urine   

<table><tr><td rowspan=2 colspan=1>HCGConcentration(mIU/mL)</td><td rowspan=1 colspan=2>Site 1Lot 1</td><td rowspan=1 colspan=2>Site 2Lot 2</td><td rowspan=1 colspan=2>Site 3Lot 3</td><td rowspan=1 colspan=2>Totalresult</td><td rowspan=2 colspan=1>%Negative</td><td rowspan=2 colspan=1>%Positive</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>78.9</td><td rowspan=1 colspan=1>21.1</td></tr><tr><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>45.6</td><td rowspan=1 colspan=1>54.4</td></tr><tr><td rowspan=1 colspan=1>17.5</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr></table>

Cut-off values of $1 0 \mathrm { m I U / m L }$ for serum and $2 0 \mathrm { m U / m L }$ for urine are verified.

b. Stability Stable at $4 { - } 3 0 ^ { \circ } \mathrm { C }$ for 24 months based on the shelf time stability study.

# c. Specificity / Cross Reactivity

# High Dose Effect

Negative urine and serum samples from females were spiked with varying high HCG concentrations ranging from 500 to $2 , 0 0 0 , 0 0 0 \mathrm { m I U / m L }$ . The spiked samples were

tested by 3 different lots and 3 different operators. No hook effect was observed at these concentrations.

# Effects of hCG $\beta$ -core fragment

Negative and positive samples (5 and $1 0 \ \mathrm { m I U / m L }$ HCG in serum; 10 and $2 0 \mathrm { m U / m L }$ HCG in urine) were spiked with various concentrations of $\beta$ -core fragment HCG (0 to $2 \mathrm { x } 1 0 ^ { 6 } \mathrm { p m o l / L } )$ . These samples were tested by 3 different lots and 3 different operators. No difference was observed for different lots and different operators. No interference was observed for these samples with $2 \mathrm { x } 1 0 ^ { 6 } \mathrm { p m o l / L }$ $\beta$ -core fragment hCG for the devices.

# Effects of glycoprotein LH, FSH and TSH

Negative and positive samples from females (10 and $2 0 \mathrm { m U / m L }$ HCG for urine, and 5 and $1 0 \ \mathrm { m I U / m L }$ HCG for serum) were spiked with various concentrations of other glycoprotein hormones such as LH, FSH, and TSH. Samples were tested using three different lots by three operators. No interference was observed for these samples for the device at LH concentrations up to $5 0 0 ~ \mathrm { m I U / m L }$ , FSH concentrations up to 1000 $\mathrm { m U / m L }$ , and TSH concentrations up to $1 0 0 0 ~ \mathrm { \mu I U / m L }$ .

# d. Interference

To evaluate potential interference from certain exogenous compounds, each interferent was made at 100X concentrate bulk and spiked in both HCG negative $\mathrm { 5 m I U / m L }$ for serum, $1 0 \mathrm { m I U / m L }$ for urine) and HCG positive $\mathrm { 1 0 m I U / m L }$ for serum, $2 0 \mathrm { m I U / m L }$ for urine) samples. All urine and serum samples were taken from women. Each spiked urine sample was mixed for 5 minutes to ensure a homogeneous solution before testing. Each sample was tested using 3 different lots of the testing kit. Results are shown in the following table which lists the highest concentration tested that did not cause positive or negative interference in either serum or urine samples.

<table><tr><td colspan="1" rowspan="1">Interferents</td><td colspan="1" rowspan="1">Concentration</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">20 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Acetoacetic Acid</td><td colspan="1" rowspan="1">2000 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Ascorbic Acid</td><td colspan="1" rowspan="1">20 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Atropine</td><td colspan="1" rowspan="1">20 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic acid</td><td colspan="1" rowspan="1">20 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Albumin</td><td colspan="1" rowspan="1">2000mg/dL</td></tr><tr><td colspan="1" rowspan="1">Bilirubin</td><td colspan="1" rowspan="1">40mg/dL</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">20 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">20mg/dL</td></tr><tr><td colspan="1" rowspan="1">Ephedrine</td><td colspan="1" rowspan="1">20 mg/dL</td></tr><tr><td colspan="1" rowspan="1">EDTA</td><td colspan="1" rowspan="1">80 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Ethanol</td><td colspan="1" rowspan="1">1%</td></tr><tr><td colspan="1" rowspan="1">Gentisic Acid</td><td colspan="1" rowspan="1">20 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Glucose</td><td colspan="1" rowspan="1">2000mg/dL</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">2000mg/dL</td></tr><tr><td colspan="1" rowspan="1">Methadone</td><td colspan="1" rowspan="1">20mg/dL</td></tr><tr><td colspan="1" rowspan="1">Phenylpropanolamine</td><td colspan="1" rowspan="1">20 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Phenothiazine</td><td colspan="1" rowspan="1">20 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Pregnanediol</td><td colspan="1" rowspan="1">2 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Salicylic Acid</td><td colspan="1" rowspan="1">20 mg/dL</td></tr><tr><td colspan="1" rowspan="1">B-hydroxybutyrate</td><td colspan="1" rowspan="1">2000mg/dL</td></tr><tr><td colspan="1" rowspan="1">Benzoylecgonine</td><td colspan="1" rowspan="1">10mg/dL</td></tr><tr><td colspan="1" rowspan="1">Cannabinol</td><td colspan="1" rowspan="1">10mg/dL</td></tr><tr><td colspan="1" rowspan="1">Methanol</td><td colspan="1" rowspan="1">10%</td></tr><tr><td colspan="1" rowspan="1">Estriol-17-beta</td><td colspan="1" rowspan="1">2mg/dL</td></tr><tr><td colspan="1" rowspan="1">Thiophene</td><td colspan="1" rowspan="1">20mg/dL</td></tr><tr><td colspan="1" rowspan="1">Ampicillin</td><td colspan="1" rowspan="1">20mg/dL</td></tr><tr><td colspan="1" rowspan="1">Tetracycline</td><td colspan="1" rowspan="1">20mg/dL</td></tr><tr><td colspan="1" rowspan="1">Ketone</td><td colspan="1" rowspan="1">20mg/dL</td></tr><tr><td colspan="1" rowspan="1">Uric Acid</td><td colspan="1" rowspan="1">20 mg/dL</td></tr><tr><td colspan="1" rowspan="1">High-density lipoprotein(serum only)</td><td colspan="1" rowspan="1">70mg/dL</td></tr><tr><td colspan="1" rowspan="1">Triglycerides(serum only)</td><td colspan="1" rowspan="1">1200mg/dL</td></tr><tr><td colspan="1" rowspan="1">Total cholesterol(serum only)</td><td colspan="1" rowspan="1">250mg/dL</td></tr></table>

e.Effect of Urine Specific Gravity and Urine pH   
Negative and positive urine samples containing 10 and $2 0 \mathrm { m U / m L }$ HCG were tested at pH values from 4 to 9 and at specific gravity values ranging from 1.000 to 1.035 using 3 different lots by 3 different operators. Data show that there is no interference from pH ranging from 4 to 9 and specific gravity ranging from 1.000 to 1.035 of tested urine samples.

# f. Comparison Studies

A method comparison study was performed, comparing the results obtained from the Innovita HCG Pregnancy Rapid Combo Test to the results from predicate devices (K203272). 108 urine and 102 serum samples were collected from 210 women (all of these women expect themselves to be pregnant, early stage at less than 5 weeks, and have not undergone any at home or in office pregnancy testing before participating in this study) from three testing sites. Samples were randomly collected at various times throughout the day. Ages ranged from 20 to 49 years old. Samples were tested by different health professionals with the proposed and the predicate devices at each site. The obtained results are shown in the following tables.

Summary Results for Urine Cassette   

<table><tr><td colspan="1" rowspan="2">New Device</td><td colspan="1" rowspan="1">Predicate device</td><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">+</td><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">0</td></tr><tr><td></td><td></td><td>0</td><td>56</td></tr></table>

# Summary Results for Serum Cassette

<table><tr><td rowspan=3 colspan=1>New Device</td><td rowspan=1 colspan=1>Predicate device</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>55</td></tr></table>

The study result shows $100 \%$ agreement for all samples to the predicate device.

g.Clinical Studies Not applicable

11. Conclusion

Based on the test principle and acceptable performance characteristics including precision, interference, specificity and method comparison of the devices, it’s concluded that Innovita HCG Pregnancy Rapid Combo Test is substantially equivalent to the predicate.